• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.

作者信息

Wang Dong, Du Ruikai, Liu Suling

机构信息

The CAS Key Laboratory of Innate Immunity and Chronic Disease, Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Science and Medical Center, University of Science & Technology of China, Hefei, 230027, Anhui, P. R. China.

Key Laboratory of Breast Cancer in Shanghai, Cancer Institute, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.

出版信息

Chin J Cancer. 2017 Mar 30;36(1):37. doi: 10.1186/s40880-017-0204-9.

DOI:10.1186/s40880-017-0204-9
PMID:28359295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5372300/
Abstract
摘要

相似文献

1
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.在三阴性乳腺癌中，Rad51抑制使乳腺癌干细胞对PARP抑制剂敏感。
Chin J Cancer. 2017 Mar 30;36(1):37. doi: 10.1186/s40880-017-0204-9.
2
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.RAD51 介导三阴性乳腺癌肿瘤干细胞对 PARP 抑制剂的耐药性。
Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
3
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.三阴性乳腺癌中聚（ADP-核糖）聚合酶（PARP）和组蛋白去乙酰化酶（HDAC）的联合靶向治疗：BRCA 突变细胞中更高的协同作用。
Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
4
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.组蛋白去乙酰化酶抑制剂，辛二酰苯胺异羟肟酸（SAHA），增强了聚（ADP - 核糖）聚合酶（PARP）抑制剂奥拉帕尼在三阴性乳腺癌细胞中的抗肿瘤作用。
Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.
5
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.CDK12抑制可逆转三阴性乳腺癌BRCA野生型和突变模型中的原发性和获得性PARP抑制剂耐药性。
Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
6
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.BRCA 基因突变与三阴性乳腺癌中的聚（ADP-核糖）聚合酶抑制剂。
Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13.
7
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.CDK12/13 抑制剂诱导三阴性乳腺癌的 BRCAness 可改善化疗效果。
Cancer Cell. 2019 Nov 11;36(5):461-463. doi: 10.1016/j.ccell.2019.10.012.
8
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.CDK1 抑制剂 RO3306 可提高 BRCA 阳性乳腺癌细胞对 PARP 抑制的反应。
Int J Oncol. 2014 Mar;44(3):735-44. doi: 10.3892/ijo.2013.2240. Epub 2013 Dec 31.
9
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.聚（ADP-核糖）聚合酶抑制剂Zj6413，作为一种潜在的抗乳腺癌治疗药物。
Biochem Pharmacol. 2016 May 1;107:29-40. doi: 10.1016/j.bcp.2016.02.015. Epub 2016 Feb 24.
10
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.聚腺苷二磷酸核糖聚合酶抑制剂与 MYC 阻断联合应用的合成致死性不依赖于三阴性乳腺癌的 BRCA 状态。
Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

引用本文的文献

1
RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer.RAD51是一种胰腺癌预后的潜在标志物，并调控细胞增殖。
Cancer Cell Int. 2019 Dec 27;19:356. doi: 10.1186/s12935-019-1077-6. eCollection 2019.
2
Limiting tumor seeding as a therapeutic approach for metastatic disease.限制肿瘤播种作为转移性疾病的治疗方法。
Pharmacol Ther. 2019 Jul;199:117-128. doi: 10.1016/j.pharmthera.2019.03.007. Epub 2019 Mar 12.
3
CAPER as a therapeutic target for triple negative breast cancer.Caper作为三阴性乳腺癌的治疗靶点。
Oncotarget. 2018 Jul 13;9(54):30340-30354. doi: 10.18632/oncotarget.25719.
4
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.依托泊苷对不同乳腺癌细胞系中 BRCA1 表达的影响。
Drugs R D. 2017 Dec;17(4):569-583. doi: 10.1007/s40268-017-0208-6.

本文引用的文献

1
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.RAD51 介导三阴性乳腺癌肿瘤干细胞对 PARP 抑制剂的耐药性。
Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
2
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.原发肿瘤中 ERCC1 和 BRAC1 mRNA 表达水平可预测经治转移性非小细胞肺癌患者二线含铂化疗的疗效。
J Thorac Oncol. 2012 Apr;7(4):663-71. doi: 10.1097/JTO.0b013e318244bdd4.
3
PARP inhibitors: its role in treatment of cancer.聚（ADP-核糖）聚合酶抑制剂：其在癌症治疗中的作用。
Chin J Cancer. 2011 Jul;30(7):463-71. doi: 10.5732/cjc.011.10111.
4
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效：一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
5
ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.ELDA：用于在干细胞及其他检测中比较耗尽和富集群体的极限稀释分析。
J Immunol Methods. 2009 Aug 15;347(1-2):70-8. doi: 10.1016/j.jim.2009.06.008. Epub 2009 Jun 28.
6
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.乳腺癌细胞系包含具有转移能力和独特分子特征的功能性癌症干细胞。
Cancer Res. 2009 Feb 15;69(4):1302-13. doi: 10.1158/0008-5472.CAN-08-2741. Epub 2009 Feb 3.
7
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.醛脱氢酶1（ALDH1）是正常和恶性人乳腺干细胞的标志物，也是临床预后不良的预测指标。
Cell Stem Cell. 2007 Nov;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.
8
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.除了乳腺癌和卵巢癌，BRCA1/2 通路还能预防血液系统癌症。
BMC Cancer. 2007 Aug 6;7:152. doi: 10.1186/1471-2407-7-152.
9
The Rad51/RadA N-terminal domain activates nucleoprotein filament ATPase activity.Rad51/RadA的N端结构域激活核蛋白丝ATP酶活性。
Structure. 2006 Jun;14(6):983-92. doi: 10.1016/j.str.2006.04.001.
10
Cancer susceptibility and the functions of BRCA1 and BRCA2.癌症易感性以及BRCA1和BRCA2的功能。
Cell. 2002 Jan 25;108(2):171-82. doi: 10.1016/s0092-8674(02)00615-3.